Download PDF
Digestive Disease Interventions 2017; 01(03): 218-224
DOI: 10.1055/s-0037-1607429
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Locoregional Therapy for Hepatic Neuroendocrine Metastases

Zachary L. Bercu
1   Division of Interventional Radiology, Department of Radiology, Emory University School of Medicine, Atlanta, Georgia
,
Jason Mitchell
1   Division of Interventional Radiology, Department of Radiology, Emory University School of Medicine, Atlanta, Georgia
,
Juan Camacho
2   Division of Interventional Radiology, Department of Radiology, Medical University of South Carolina, Charleston, South Carolina
,
Darren D. Kies
1   Division of Interventional Radiology, Department of Radiology, Emory University School of Medicine, Atlanta, Georgia
,
Eric Friedberg
3   Department of Radiology, Emory University School of Medicine, Atlanta, Georgia
,
Charles Martin
4   Division of Interventional Radiology, Department of Radiology, Cleveland Clinic Foundation, Cleveland, Ohio
,
J. David Prologo
1   Division of Interventional Radiology, Department of Radiology, Emory University School of Medicine, Atlanta, Georgia
› Author Affiliations
Further Information

Publication History

27 May 2017

05 September 2017

Publication Date:
01 November 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Neuroendocrine tumors are a heterogeneous group of malignancies with diverse biological and clinical behavior. Locoregional treatments available for the initial and temporal management of neuroendocrine tumors involving the liver include transarterial embolization, transarterial chemoembolization, selective internal radiotherapy, and ablative techniques. These therapies are best employed as part of a multidisciplinary management team focusing on appropriate histopathology, timing, and individuality of each intervention.

Keywords

hepatic - locoregional - neuroendocrine
 

  • References

  • 1 Cho MY, Kim JM, Sohn JH. , et al; Gastrointestinal Pathology Study Group of Korean Society of Pathologists. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 2012; 44 (03) 157-165
    CrossrefPubMedGoogle Scholar
  • 2 Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39 (06) 707-712
    CrossrefPubMedGoogle Scholar
  • 3 Klöppel G, Couvelard A, Perren A. , et al; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90 (02) 162-166
    CrossrefPubMedGoogle Scholar
  • 4 Norheim I, Oberg K, Theodorsson-Norheim E. , et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206 (02) 115-125
    CrossrefPubMedGoogle Scholar
  • 5 Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013; 24 (12) 3040-3044
    CrossrefPubMedGoogle Scholar
  • 6 Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol 2009; 100 (08) 635-638
    CrossrefPubMedGoogle Scholar
  • 7 Yao JC, Hassan M, Phan A. , et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
    CrossrefPubMedGoogle Scholar
  • 8 Hauso O, Gustafsson BI, Kidd M. , et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113 (10) 2655-2664
    CrossrefPubMedGoogle Scholar
  • 9 Öberg K. Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10 (Suppl. 02) S3-S8
    PubMedGoogle Scholar
  • 10 Godwin II JD. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975; 36 (02) 560-569
    CrossrefPubMedGoogle Scholar
  • 11 McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81 (07) 1007-1009
    CrossrefPubMedGoogle Scholar
  • 12 Zeitels J, Naunheim K, Kaplan EL, Straus II F. Carcinoid tumors: a 37-year experience. Arch Surg 1982; 117 (05) 732-737
    CrossrefPubMedGoogle Scholar
  • 13 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97 (04) 934-959
    CrossrefPubMedGoogle Scholar
  • 14 Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumours. Berlin, Heidelberg: Springer Science & Business Media; 2012
    Google Scholar
  • 15 Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol 2014; 25 (02) 186-192
    CrossrefPubMedGoogle Scholar
  • 16 Pavel M, Baudin E, Couvelard A. , et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95 (02) 157-176
    CrossrefPubMedGoogle Scholar
  • 17 Veenendaal LM, Borel Rinkes IH, Lips CJ, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 2006; 4 (01) 35
    CrossrefPubMedGoogle Scholar
  • 18 Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 1999; 11 (01) 38-41
    CrossrefPubMedGoogle Scholar
  • 19 Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006; 17 (08) 1235-1249 , quiz 1250
    CrossrefPubMedGoogle Scholar
  • 20 Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin N-EA. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72 (03) 517-528
    CrossrefPubMedGoogle Scholar
  • 21 Richard R, Warner P, Kang Kim M. Carcinoid and related neuroendocrine tumors. In: Geschwind J-FH, Soulen MC. , eds. Interventional Oncology: Principles and Practice. New York, NY: Cambridge University Press; 2008: 290-300
    CrossrefGoogle Scholar
  • 22 Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180 (05) 1379-1384
    CrossrefPubMedGoogle Scholar
  • 23 Ho AS, Picus J, Darcy MD. , et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188 (05) 1201-1207
    CrossrefPubMedGoogle Scholar
  • 24 Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Contr 2006; 13 (01) 72-78
    PubMedGoogle Scholar
  • 25 Sofocleous CT, Petre EN, Gonen M. , et al. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol 2014; 25 (01) 22-30 , quiz 31
    CrossrefPubMedGoogle Scholar
  • 26 Bodei L, Kidd M, Paganelli G. , et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015; 42 (01) 5-19
    CrossrefPubMedGoogle Scholar
  • 27 Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 2010; 14 (04) 347-351
    PubMedGoogle Scholar
  • 28 Pitt SC, Knuth J, Keily JM. , et al. Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg 2008; 12 (11) 1951-1960
    CrossrefPubMedGoogle Scholar
  • 29 Gupta S, Johnson MM, Murthy R. , et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
    CrossrefPubMedGoogle Scholar
  • 30 Fiore F, Del Prete M, Franco R. , et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 2014; 47 (01) 177-182
    CrossrefPubMedGoogle Scholar
  • 31 Eriksson BK, Larsson EG, Skogseid BM, Löfberg A-M, Lörelius L-E, Öberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83 (11) 2293-2301
    CrossrefPubMedGoogle Scholar
  • 32 Kennedy A, Nag S, Salem R. , et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68 (01) 13-23
    CrossrefPubMedGoogle Scholar
  • 33 Dawson LA, McGinn CJ, Normolle D. , et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18 (11) 2210-2218
    CrossrefPubMedGoogle Scholar
  • 34 Salem R, Lewandowski RJ, Sato KT. , et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007; 10 (01) 12-29
    CrossrefPubMedGoogle Scholar
  • 35 Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 2010; 251 (05) 910-916
    CrossrefPubMedGoogle Scholar
  • 36 Paprottka PM, Hoffmann RT, Haug A. , et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 2012; 35 (02) 334-342
    CrossrefPubMedGoogle Scholar
  • 37 Kennedy AS, Dezarn WA, McNeillie P. , et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31 (03) 271-279
    CrossrefPubMedGoogle Scholar
  • 38 Murthy R, Kamat P, Nunez R. , et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 2008; 19 (01) 145-151
    CrossrefPubMedGoogle Scholar
  • 39 van Hazel GA, Heinemann V, Sharma NK. , et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15) 1723-1731
    CrossrefPubMedGoogle Scholar
  • 40 Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J 2010; 16 (02) 111-117
    CrossrefPubMedGoogle Scholar
  • 41 Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997; 122 (06) 1040-1047 , discussion 1047–1048
    CrossrefPubMedGoogle Scholar
  • 42 Giovannini M, Seitz JF. Ultrasound-guided percutaneous alcohol injection of small liver metastases. Results in 40 patients. Cancer 1994; 73 (02) 294-297
    CrossrefPubMedGoogle Scholar
  • 43 Livraghi T, Vettori C, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 1991; 179 (03) 709-712
    CrossrefPubMedGoogle Scholar
  • 44 Giovannini M. Percutaneous alcohol ablation for liver metastasis. Semin Oncol 2002; 29 (02) 192-195
    CrossrefPubMedGoogle Scholar
  • 45 Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 1998; 14 (02) 175-183
    CrossrefPubMedGoogle Scholar
  • 46 de Baere T, Deschamps F, Tselikas L. , et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 2015; 172 (04) R151-R166
    CrossrefPubMedGoogle Scholar
  • 47 Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26 (08) 985-990
    CrossrefPubMedGoogle Scholar
  • 48 Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142 (01) 10-19
    CrossrefPubMedGoogle Scholar
  • 49 Lorentzen T. A cooled needle electrode for radiofrequency tissue ablation: thermodynamic aspects of improved performance compared with conventional needle design. Acad Radiol 1996; 3 (07) 556-563
    CrossrefPubMedGoogle Scholar
  • 50 de Baere T, Elias D, Dromain C. , et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175 (06) 1619-1625
    CrossrefPubMedGoogle Scholar
  • 51 Solbiati L, Livraghi T, Goldberg SN. , et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221 (01) 159-166
    CrossrefPubMedGoogle Scholar
  • 52 Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30 (04) 435-441
    CrossrefPubMedGoogle Scholar
  • 53 Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010; 148 (06) 1288-1293 , discussion 1293
    CrossrefPubMedGoogle Scholar
  • 54 Mohan H, Nicholson P, Winter DC. , et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 2015; 26 (07) 935-942.e1
    CrossrefPubMedGoogle Scholar
  • 55 Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee Jr FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005; 236 (01) 132-139
    CrossrefPubMedGoogle Scholar
  • 56 Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010; 17 (01) 171-178
    CrossrefPubMedGoogle Scholar
  • 57 Walker K, Lindeque B. The application of cryoprobe therapy in orthopedic oncology. Orthopedics 2014; 37 (08) 536-540
    CrossrefPubMedGoogle Scholar
  • 58 Liu YY, Chiang PH, Chuang YC, Lee WC, Cheng YT, Wang HJ. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. Ann Surg Oncol 2015; 22 (05) 1612-1617
    PubMedGoogle Scholar
  • 59 Yu H, Burke CT. Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors. Semin Intervent Radiol 2014; 31 (02) 129-137
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int 2005; 95 (09) 1187-1191
    CrossrefPubMedGoogle Scholar
  • 61 Scheffer HJ, Nielsen K, de Jong MC. , et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 2014; 25 (07) 997-1011 , quiz 1011 quiz
    CrossrefPubMedGoogle Scholar
  • 62 Thomson KR, Cheung W, Ellis SJ. , et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22 (05) 611-621
    CrossrefPubMedGoogle Scholar
  • 63 Kingham TP, Karkar AM, D'Angelica MI. , et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215 (03) 379-387
    CrossrefPubMedGoogle Scholar
  • 64 Ebara M, Okabe S, Kita K. , et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43 (03) 458-464
    CrossrefPubMedGoogle Scholar
  • 65 Atwell TD, Charboneau JW, Que FG. , et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005; 28 (04) 409-421
    CrossrefPubMedGoogle Scholar
  • 66 Lahat E, Eshkenazy R, Zendel A. , et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr 2014; 3 (05) 317-323
    PubMedGoogle Scholar
  • 67 Adam R, Hagopian EJ, Linhares M. , et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002; 137 (12) 1332-1339 , discussion 1340
    CrossrefPubMedGoogle Scholar
  • 68 Pearson AS, Izzo F, Fleming RY. , et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999; 178 (06) 592-599
    CrossrefPubMedGoogle Scholar